The pharmaceutical company Croda Pharma, member of CATALONIA.HEALTH, announces the launch of Super RefinedTM Poloxamer 188, an innovative bioprocessing solution developed to meet the growing demands of biopharmaceutical development.
Officially, it was launched on 16 October at the Festival of Biologics in Basel, Switzerland, where James Humphrey, a research and technology specialist at Croda Pharma, presented the last solution for shear stress in cell culture.
On October 29, in collaboration with BioProcess International, Croda Pharma held a global webinar to present the Poloxamer 188 Super RefinedTM solution and the expanded bioprocessing range. With this launch, Croda addresses critical challenges in biopharmaceutical development and strengthens the commitment to innovation and patient safety in advanced therapeutic formulations.
Katie Dec, global business director of Croda Pharma, values how “this marks another exciting chapter in our evolution, providing our deep experience in purifying ingredients for pharmaceutical applications in the field of bioprocessing”.
Comments